Earnings Feed
Start Free
Aclaris Therapeutics, Inc.·4

Jun 8, 4:15 PM ET

SCHIFF ANDREW N 4

Research Summary

AI-generated summary

Updated

Aclaris (ACRS) Director Andrew Schiff Receives RSUs, Exercises 11,580

What Happened

  • Andrew N. Schiff, a director of Aclaris Therapeutics (ACRS), received equity awards and completed a same‑day conversion/disposition of derivative securities. On June 4, 2026 he was granted two awards totaling 53,337 restricted stock units (42,350 + 10,987) at $0.00. On June 5, 2026 the filing shows an exercise/conversion of 11,580 derivative shares (acquired) and an immediate disposition of 11,580 shares (reported proceeds $0.00).
  • These were awards/derivative transactions (not open‑market purchases or sales for cash). Awards were granted at no cash price; the reported $0 disposition proceeds mean the filing does not show cash proceeds from the same‑day disposition.

Key Details

  • Transaction dates and reported prices:
    • 2026-06-04: Grant/award of 42,350 RSUs and 10,987 RSUs, $0.00 per unit (total = 53,337 RSUs).
    • 2026-06-05: Exercise/conversion of 11,580 derivative shares (acquired; price N/A) and same‑day disposition of 11,580 shares (reported proceeds $0.00).
  • Shares owned after the transactions: Not specified in the provided filing.
  • Notable footnotes from the filing:
    • F1: Each RSU represents a contingent right to one share of common stock.
    • F6: The shares underlying these RSUs vested on June 5, 2026.
    • F4/F5: Grants were made under the director compensation policy/issuer plan; some awards vest according to plan schedules.
    • F2: Some reportable securities are held by Aisling Capital entities; Dr. Schiff disclaims beneficial ownership of those securities except to the extent of any pecuniary interest.
  • Filing timeliness: The report was filed June 8, 2026 for transactions on June 4–5; the filing does not indicate a late filing status.

Context

  • RSUs are awards (not purchases) and only become shares if/when they vest; the filing confirms vesting occurred June 5 for the RSUs referenced.
  • The same‑day conversion followed by a $0 reported disposition is commonly associated with share settlement or withholding arrangements (the filing does not explain the reason), so this is not presented as an open‑market sale for cash.
  • The filing includes institutional/partnership ownership details (Aisling entities) and a disclaimer by Dr. Schiff about beneficial ownership of those holdings.